Valuation: Senzime AB

Market Cap 660M 67.88M 59.44M 54.87M 51.24M 96.45M 6.42B 98.65M 255M 3.17B 255M 249M 10.99B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 660M 67.88M 59.44M 54.87M 51.24M 96.45M 6.42B 98.65M 255M 3.17B 255M 249M 10.99B EV / Sales 2026 *
4.32x
EV / Sales 2027 * 2.84x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -
1 day+1.79%
1 week-3.06%
Current month-13.81%
1 month-5.84%
3 months+3.64%
6 months-18.73%
Current year-20.83%
1 week 4.12
Extreme 4.125
4.44
1 month 4.12
Extreme 4.125
4.8
Current year 3.85
Extreme 3.85
6
1 year 3.85
Extreme 3.85
7.38
3 years 2.95
Extreme 2.95
9.6
5 years 2.6
Extreme 2.605
26
10 years 2.6
Extreme 2.605
28.5
Manager TitleAgeSince
Chief Executive Officer 53 02/05/2023
Director of Finance/CFO 56 31/12/2021
Chief Tech/Sci/R&D Officer 50 31/12/2022
Director TitleAgeSince
Chairman 53 02/05/2023
Director/Board Member 70 31/12/2015
Director/Board Member 63 04/03/2020
Date Insider Type Main position Quantity % Market Cap.
12-08Sell

Director

15,000 0.0095%
12-08Buy

Director

15,000 0.0095%
11-27Buy

Director

15,900 0.0101%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%-3.06%-16.34%+44.92% 67.97M
-1.50%+5.56%-31.84%-13.89% 164B
-0.06%+2.09%-7.16%-6.73% 104B
-1.57%+3.82%-6.07%+47.83% 55.67B
+0.90%-5.29%+52.20%+53.60% 52.92B
-0.47%+10.29%-9.90%-40.43% 42.96B
+1.90%+14.12% - - 32.87B
-0.23%+1.32%-19.83%-45.30% 27.07B
+1.09%+7.57%+62.10%-6.01% 24.79B
-1.13%+6.41%-11.23%-3.51% 21.02B
Average +0.09%+2.95%+1.33%+3.39% 52.5B
Weighted average by Cap. -0.47%+3.98%-6.50%-1.34%

Financials

2026 *2027 *
Net sales 153M 15.7M 13.75M 12.69M 11.85M 22.31M 1.48B 22.81M 58.95M 732M 58.95M 57.66M 2.54B 232M 23.88M 20.91M 19.3M 18.03M 33.93M 2.26B 34.71M 89.68M 1.11B 89.68M 87.72M 3.87B
Net income -65.3M -6.71M -5.88M -5.43M -5.07M -9.54M -635M -9.76M -25.21M -313M -25.21M -24.66M -1.09B -26.3M -2.7M -2.37M -2.19M -2.04M -3.84M -256M -3.93M -10.15M -126M -10.15M -9.93M -438M
Net Debt - -
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume
29/06/26 SEK 4.275 +1.79% 76,135
26/06/26 SEK 4.200 -2.33% 74,180
25/06/26 SEK 4.300 0.00% 49,120
24/06/26 SEK 4.300 0.00% 311,404
23/06/26 SEK 4.300 -1.49% 52,710

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SEZI Stock